NME3, human recombinant protein
Nucleoside diphosphate kinase 3, c371H6.2, DR-nm23, KIAA0516, NDPK-C, NDPKC, NM23-H3, NM23H3.
|Calculated MW||19.1 kDa (169 aa, 22-169 aa + His Tag)|
|Other Names||Nucleoside diphosphate kinase 3, c371H6.2, DR-nm23, KIAA0516, NDPK-C, NDPKC, NM23-H3, NM23H3.|
|Results||Specific activity is > 20 units/ml|
|Sequence||MGSSHHHHHH SSGLVPRGSH MERTFLAVKP DGVQRRLVGE IVRRFERKGF KLVALKLVQA SEELLREHYA ELRERPFYGR LVKYMASGPV VAMVWQGLDV VRTSRALIGA TNPADAPPGT IRGDFCIEVG KNLIHGSDSV ESARREIALW FRADELLCWE DSAGHWLYE|
|Storage||-20°C; 0.5 mg/ml solution in 20 mM Tris-HCl buffer (pH 8.0) containing 50% glycerol, 0.1 M NaCl and 2 mM DTT|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
NME3, also known as, a potential suppressor of metastasis, is expressed at a much lower level in highly metastatic cells than in cells with lower metastatic potential. It is important for the synthesis of nucleoside triphosphates and may play a role in apoptosis induction and hematopoiesis. It is preferentially expressed during early stages of myeloid differentiation of highly purified CD34+ cells. Recombinant human NME3 protein, fused to His-tag at N-terminus, was expressed in E.coli and purified by using conventional chromatography.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.